Who is sponsoring NCT03395145?

NCT03395145 is sponsored by Rambam Health Care Campus.

What drugs are being tested in NCT03395145?

Interventions in NCT03395145: Geistlich Bio-Oss® Collagen and Geistlich Mucograft® Seal.

What condition does NCT03395145 study?

NCT03395145 studies Bio-Oss; Mucograft.

Is NCT03395145 still recruiting?

NCT03395145 is currently completed. Last updated 4 April 2023.

Last reviewed 2023-04-04 · How we verify

NCT03395145

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bone Volume Changes After Socket Preservation Using Geistlich Bio-Oss Collagen and Mucograft Seal

Completed NA Last updated 4 April 2023

What this trial tests

NA trial testing Geistlich Bio-Oss® Collagen and Geistlich Mucograft® Seal in Bio-Oss; Mucograft in 30 participants. Completed in 17 July 2022.

Timeline

27 May 2018

Primary endpoint
17 July 2022

17 July 2022

Quick facts

Lead sponsor	Rambam Health Care Campus
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	30
Start date	27 May 2018
Primary completion	17 July 2022
Estimated completion	17 July 2022
Sites	1 location across Israel

Drugs / interventions tested

Geistlich Bio-Oss® Collagen and Geistlich Mucograft® Seal

Conditions studied

Bio-Oss; Mucograft — all drugs for Bio-Oss; Mucograft →

Sponsor

Rambam Health Care Campus — full company profile →

Who can join

18 and older, any sex, with Bio-Oss; Mucograft. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Evaluation of Bone volume Changes after socket preservation using Geistlich Bio-Oss® Collagen and Geistlich Mucograft® Seal compared to natural healing after tooth extraction

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Rambam Health Care Campus trials

Trials by the same sponsor.

NCT07384013 — Study Protocol: Impact of Metamizole (Optalgin®) on Anti-Xa Concentrations in Oncology Patients Receiving DOACs · NA · recruiting
NCT06688253 — Intravenous Human IgG1 Fc Fragment (Efgartigimod) in Myasthenic Crisis · Phase 4 · not yet recruiting
NCT06235749 — Administration Of Calcium Gluconate for The Reduction of Blood Loss During Elective Cesarean Delivery · NA · recruiting
NCT06622902 — Influence of Flow Rate Change on CO2 Levels During High Flow Nasal Ventilation (HFNV) in Preterm Infants. · NA · recruiting
NCT05922111 — Cervical Ripening Balloon for 12 Hours vs. 1 Hour. · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03395145 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Rambam Health Care Campus
Last refreshed: 4 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03395145.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing